BioCentury
ARTICLE | Clinical News

Oncotype DX identifies breast cancer patients who can be spared chemotherapy

June 3, 2018 7:37 PM UTC

An open-label, international Phase III trial conducted by NCI showed that the Oncotype DX breast cancer assay from Genomic Health Inc. (NASDAQ:GHDX) identified a subgroup of women with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer who do not require chemotherapy following surgery. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago and published in the New England Journal of Medicine.

In the 10,273-patient TAILORx study, women screened with Oncotype DX who had a "mid-range" Recurrence Score (RS) of 11-25 and received hormone therapy alone were found to have a similar nine-year invasive disease-free survival (DFS) rate, the primary endpoint, compared with "mid-range" RS patients who receive hormone therapy plus chemotherapy in the adjuvant setting (83.3% vs. 84.3%, HR=1.08, 95% CI: 0.94, 1.24, p=0.26). The rates were also similar between treatment arms for distant recurrence-free interval (94.5% vs. 95%, HR=1.03, p=0.8), recurrence-free interval (92.2% vs. 92.9%, HR=1.12, p=0.28) and nine-year overall survival (93.9% vs. 93.8%, HR=0.97, p=0.8)...